Regenxbio racks up $70.5 mln Series D

Rockville, Maryland-based Regenxbio, a gene therapy-focused biotech company, has closed $70.5 million in Series D funding. Vivo Capital, Venrock and Brookside Capital led the round with participation from other investors that included Janus Capital Management LLC, Perceptive Advisors LLC, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management LLC, Foresite Capital Management, Deerfield Management and Fidelity Biosciences. Chardan Capital Markets LLC was the placement agent.

North AmericaUSBriefs